Son zamanlarda hematolojik onkoloji alan\u0131nda dikkat \u00e7eken bir \u00e7al\u0131\u015fma, diffuse b\u00fcy\u00fck B h\u00fccreli lenfoma (DLBCL) hastalar\u0131n\u0131n periferik kanlar\u0131nda bulunan miyeloid kaynakl\u0131 bask\u0131lay\u0131c\u0131 h\u00fccrelerin (MDSC) oranlar\u0131ndaki ve i\u015flevlerindeki belirgin anormallikleri ortaya koydu. Bu \u00f6nemli bulgular, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ile lenfoma ilerleyi\u015fi aras\u0131ndaki karma\u015f\u0131k ili\u015fkiyi anlamakta \u00f6nemli bir ad\u0131m te\u015fkil ederken, te\u015fhis ve tedavi uygulamalar\u0131nda yeni ufuklar a\u00e7may\u0131 vaat ediyor. MDSC\u2019ler, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131layan etkili \u00f6zelliklere sahip, olgunla\u015fmam\u0131\u015f miyeloid h\u00fccre grubudur ve farkl\u0131 kanser t\u00fcrlerinde bu h\u00fccrelerin rol\u00fc gittik\u00e7e artan bir ilgi oda\u011f\u0131d\u0131r. Ancak DLBCL \u00f6zelinde bu h\u00fccrelerin ba\u011f\u0131\u015f\u0131kl\u0131k dengesine katk\u0131s\u0131 uzun zamand\u0131r belirsizli\u011fini koruyordu.<\/p>\n
Bilim insanlar\u0131, yeni tan\u0131 konmu\u015f DLBCL hastalar\u0131 ile sa\u011fl\u0131kl\u0131 bireylerin periferik kan \u00f6rneklerindeki MDSC oranlar\u0131n\u0131 ak\u0131ll\u0131 ak\u0131\u015f sitometrisi y\u00f6ntemleri ile hassas \u015fekilde \u00f6l\u00e7\u00fcmledi. H\u00fccrelerin sadece say\u0131sal verileri de\u011fil, ayn\u0131 zamanda apoptosiz (programlanm\u0131\u015f h\u00fccre \u00f6l\u00fcm\u00fc) ve proliferasyon (\u00e7o\u011falma) oranlar\u0131 da incelenerek MDSC\u2019lerin t\u00fcm h\u00fccresel dinamikleri detayl\u0131 bi\u00e7imde analiz edildi. Bu, malignitenin yaratabilece\u011fi h\u00fccresel de\u011fi\u015fikliklerin anla\u015f\u0131lmas\u0131n\u0131n yan\u0131 s\u0131ra MDSC\u2019lerin nas\u0131l \u00e7o\u011fald\u0131\u011f\u0131 veya i\u015flev olarak nas\u0131l yeniden programland\u0131\u011f\u0131n\u0131n daha iyi kavranmas\u0131n\u0131 sa\u011flad\u0131.<\/p>\n
\u00d6zellikle DLBCL hastalar\u0131ndan elde edilen veriler, MDSC\u2019lerin say\u0131s\u0131nda \u00f6nemli art\u0131\u015flar oldu\u011funu g\u00f6sterdi. Bu art\u0131\u015f, miyeloidoz ad\u0131 verilen de\u011fi\u015fik y\u00f6nde geli\u015fen kan h\u00fccresi \u00fcretimi s\u00fcrecinde, immunosupresif h\u00fccrelerin \u00e7o\u011fald\u0131\u011f\u0131na i\u015faret ediyor. T\u00fcm\u00f6r mikro\u00e7evresinin bu h\u00fccrelerin \u00fcretimini ve s\u00fcrd\u00fcr\u00fclmesini aktif \u015fekilde destekledi\u011fi d\u00fc\u015f\u00fcn\u00fclerek, v\u00fccudun ba\u011f\u0131\u015f\u0131kl\u0131k sistemine kar\u015f\u0131 i\u015flevsel bir engel olu\u015fturdu\u011fu anla\u015f\u0131ld\u0131. \u00d6nceki \u00e7al\u0131\u015fmalar farkl\u0131 kanser tiplerinde benzer e\u011filimleri bildirse de, bu \u00e7al\u0131\u015fma DLBCL ba\u011flam\u0131nda bu mekanizman\u0131n \u00f6nemini netle\u015ftirdi.<\/p>\n
MDSC\u2019lerin bu art\u0131\u015f\u0131n\u0131n fonksiyonel yans\u0131malar\u0131n\u0131 ara\u015ft\u0131rmak i\u00e7in laboratuvar ortam\u0131nda \u00f6zel ko-k\u00fclt\u00fcr deneyleri planland\u0131. \u0130zole edilen MDSC\u2019ler, DLBCL h\u00fccre hatlar\u0131yla ve hastalara ait otolog T h\u00fccreleriyle e\u015f zamanl\u0131 olarak yeti\u015ftirildi. Burada MDSC\u2019lerin hem t\u00fcm\u00f6r h\u00fccreleri \u00fczerindeki etkisi hem de T h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k fonksiyonlar\u0131n\u0131n nas\u0131l de\u011fi\u015fti\u011fi derinlemesine de\u011ferlendirildi. DLBCL h\u00fccrelerinin MDSC b\u00fcy\u00fcmesini uyard\u0131\u011f\u0131 bulgusu, tekrar eden ve ba\u011f\u0131\u015f\u0131kl\u0131k bask\u0131s\u0131n\u0131 kal\u0131c\u0131 k\u0131lan bir geri besleme d\u00f6ng\u00fcs\u00fcn\u00fc ortaya koydu.<\/p>\n
Fonsiyonel analizlerde, DLBCL hastalar\u0131ndan izole edilen MDSC\u2019lerin T h\u00fccrelerinin \u00e7o\u011falmas\u0131n\u0131 ve aktivasyonunu belirgin \u015fekilde engelledi\u011fi g\u00f6r\u00fcld\u00fc. Bu bask\u0131laman\u0131n sadece h\u00fccre say\u0131s\u0131 \u00fczerinden de\u011fil, ayn\u0131 zamanda T h\u00fccrelerinin etkili sitokin salg\u0131s\u0131n\u0131n azalmas\u0131 gibi fonksiyonel \u00f6zelliklere de yans\u0131d\u0131\u011f\u0131 belirlendi. Sonu\u00e7 olarak T h\u00fccrelerinin t\u00fcm\u00f6r h\u00fccrelerine kar\u015f\u0131 verdi\u011fi yan\u0131tta \u00f6nemli bir gerileme ya\u015fanarak, etkili antit\u00fcm\u00f6r aktivitenin \u00f6n\u00fcnde ciddi engeller olu\u015ftu.<\/p>\n
Ara\u015ft\u0131rmada, h\u00fccresel d\u00fczeydeki bu farkl\u0131l\u0131klar\u0131 molek\u00fcler tabana oturtmak i\u00e7in RNA transkriptom dizileme y\u00f6ntemleri kullan\u0131ld\u0131. MDSC\u2019lerin gen ifade profilleri kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, DLBCL kaynakl\u0131 h\u00fccrelerin imm\u00fcnosupresyonla ili\u015fkili genleri ve metabolik adapatasyon i\u00e7in kritik yollar\u0131 artm\u0131\u015f \u015fekilde aktive etti\u011fi ke\u015ffedildi. Bu molek\u00fcler bulgular, MDSC\u2019lerin nas\u0131l s\u00fcrd\u00fcr\u00fcld\u00fc\u011f\u00fcn\u00fc ve ba\u011f\u0131\u015f\u0131kl\u0131k bask\u0131s\u0131n\u0131 nas\u0131l peki\u015ftirdi\u011fini anlamada yeni hedef noktalar sundu.<\/p>\n
\u00c7al\u0131\u015fma ayr\u0131ca MDSC oranlar\u0131 ve fonksiyonlar\u0131 ile hastalar\u0131n klinik parametreleri aras\u0131nda anlaml\u0131 ba\u011flant\u0131lar kurdu. Ann Arbor evreleme sistemi, serum laktat dehidrogenaz (LDH) seviyesi ve Uluslararas\u0131 Prognostik \u0130ndeks (IPI) gibi DLBCL prognozunu etkileyen fakt\u00f6rlerle MDSC anormallikleri aras\u0131nda korelasyon tespit edildi. Bu, MDSC\u2019lerin sadece biyolojik bir detay olmaktan \u00e7\u0131karak hastal\u0131\u011f\u0131n seyri ve \u015fiddetinin belirlenmesinde potansiyel bir biyobelirte\u00e7 haline geldi\u011fini g\u00f6steriyor.<\/p>\n
Elde edilen bulgular \u0131\u015f\u0131\u011f\u0131nda, MDSC\u2019lerin hedeflenmesinin DLBCL tedavisinde ba\u011f\u0131\u015f\u0131kl\u0131k ortam\u0131n\u0131 olumlu y\u00f6nde de\u011fi\u015ftirip T h\u00fccre fonksiyonlar\u0131n\u0131 onarabilece\u011fi konusunda umut verici hipotezler ortaya konmu\u015ftur. G\u00fcn\u00fcm\u00fczde h\u0131zla geli\u015fen imm\u00fcno-onkoloji alan\u0131nda bu t\u00fcr stratejilerin, imm\u00fcnoterapilerle kombinasyon halinde kullan\u0131larak ba\u011f\u0131\u015f\u0131kl\u0131k bask\u0131s\u0131n\u0131n azalt\u0131lmas\u0131 ve do\u011frudan t\u00fcm\u00f6r h\u00fccrelerinin yok edilmesi hedeflenmektedir. Bu \u00e7al\u0131\u015fman\u0131n ortaya koydu\u011fu veriler, b\u00f6yle \u00e7ok katmanl\u0131 tedavi yakla\u015f\u0131mlar\u0131 geli\u015ftirmek i\u00e7in sa\u011flam temel te\u015fkil etmektedir.<\/p>\n
Ayr\u0131ca ara\u015ft\u0131rmada MDSC proliferasyonu ve fonksiyonunun mekanistik detaylar\u0131 hakk\u0131nda kapsaml\u0131 \u00e7al\u0131\u015fmalar yap\u0131lmas\u0131 gerekti\u011fi vurguland\u0131. Metabolik durumlar\u0131, epigenetik modifikasyonlar\u0131 ve di\u011fer ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri ile olan etkile\u015fimlerinin ara\u015ft\u0131r\u0131lmas\u0131, bu h\u00fccrelerin lenfoma i\u00e7indeki karma\u015f\u0131k rol\u00fcn\u00fc a\u00e7\u0131\u011fa \u00e7\u0131kararak klinik uygulamalara aktar\u0131labilecek yeni bulgular sa\u011flayacakt\u0131r. Bu, DLBCL tedavisini tekrar tan\u0131mlayacak ve daha etkili yakla\u015f\u0131mlar\u0131n geli\u015ftirilmesini tetikleyecektir.<\/p>\n
DLBCL t\u00fcm\u00f6r h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k mikro\u00e7evresini MDSC arac\u0131l\u0131\u011f\u0131yla aktif \u015fekilde manip\u00fcle etti\u011finin do\u011frulanmas\u0131, mevcut tedavi \u00e7er\u00e7evelerinin yeniden de\u011ferlendirilmesini gerekli k\u0131l\u0131yor. \u00d6zellikle ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131 inhibit\u00f6rleri gibi yeni nesil imm\u00fcnmod\u00fclat\u00f6rlerin yan\u0131nda, MDSC\u2019leri hedef alan tedavilerin de multipronged olarak uygulanmas\u0131, lenfoman\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k direncini k\u0131rmada kritik bir avantaj sa\u011flayabilir.<\/p>\n
Sonu\u00e7 olarak, DLBCL hastalar\u0131ndaki MDSC anormalliklerinin detayl\u0131 de\u011ferlendirilmesi, hematolojik onkoloji ara\u015ft\u0131rmalar\u0131nda \u00f6nemli bir kilometre ta\u015f\u0131d\u0131r. Bu h\u00fccrelerin T h\u00fccre fonksiyonlar\u0131n\u0131 nas\u0131l bask\u0131lad\u0131\u011f\u0131 ve t\u00fcm\u00f6r ilerlemesine nas\u0131l katk\u0131 verdi\u011fi g\u00fcn y\u00fcz\u00fcne \u00e7\u0131kar\u0131larak, yeni biyobelirte\u00e7lerin ve hedefe y\u00f6nelik tedavilerin geli\u015ftirilmesi i\u00e7in \u0131\u015f\u0131k tutulmu\u015ftur. Sadece DLBCL de\u011fil, imm\u00fcn ka\u00e7\u0131\u015f mekanizmas\u0131na sahip di\u011fer kanserler i\u00e7in de \u00f6nemli dersler i\u00e7eren bu \u00e7al\u0131\u015fma, ba\u011f\u0131\u015f\u0131kl\u0131k mikro\u00e7evresinin hassas modulasyonu ile hastalar\u0131n ya\u015fam kalitesinin ve tedavi ba\u015far\u0131lar\u0131n\u0131n art\u0131r\u0131lmas\u0131na \u00f6nc\u00fcl\u00fck edecektir.<\/p>\n
Gelecekte, ba\u011f\u0131\u015f\u0131kl\u0131k ortam\u0131n\u0131n hassas d\u00fczenlenmesi sayesinde diffuse b\u00fcy\u00fck B h\u00fccreli lenfoma, g\u00fcn\u00fcm\u00fcz\u00fcn zorlu sa\u011fl\u0131k s\u0131navlar\u0131ndan biri olmaktan \u00e7\u0131karak daha y\u00f6netilebilir ve tedavi edilebilir bir hastal\u0131\u011fa d\u00f6n\u00fc\u015febilir. Bu do\u011frultuda MDSC odakl\u0131 stratejilerin klinik uygulamalardaki yeri giderek g\u00fc\u00e7lenecek ve yeni nesil lenfoma tedavilerine entegre edilecektir. S\u00fcregelen ara\u015ft\u0131rmalar\u0131n \u0131\u015f\u0131\u011f\u0131nda, \u00f6n\u00fcm\u00fczdeki y\u0131llarda hematolojik malignansilerde devrim niteli\u011finde geli\u015fmeler ya\u015fanmas\u0131 beklenmektedir.<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Doi Referans<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Son zamanlarda hematolojik onkoloji alan\u0131nda dikkat \u00e7eken bir \u00e7al\u0131\u015fma, diffuse b\u00fcy\u00fck B h\u00fccreli lenfoma (DLBCL) hastalar\u0131n\u0131n periferik kanlar\u0131nda bulunan miyeloid kaynakl\u0131 bask\u0131lay\u0131c\u0131 h\u00fccrelerin (MDSC) oranlar\u0131ndaki ve i\u015flevlerindeki belirgin anormallikleri ortaya koydu. Bu \u00f6nemli bulgular, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ile lenfoma ilerleyi\u015fi aras\u0131ndaki karma\u015f\u0131k ili\u015fkiyi anlamakta \u00f6nemli bir ad\u0131m te\u015fkil ederken, te\u015fhis ve tedavi uygulamalar\u0131nda yeni ufuklar a\u00e7may\u0131…<\/p>\n","protected":false},"author":1,"featured_media":3791,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3005,3007,3004,3006,3008],"tmauthors":[],"class_list":{"0":"post-3790","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-diffuse-buyuk-b-hucreli-lenfoma-bagisiklik-sistemi-etkileri","9":"tag-hematolojik-onkoloji-mdsc-fonksiyonel-analizleri","10":"tag-lenfoma-miyeloid-baskilayici-hucre-dengesizligi","11":"tag-miyeloid-kaynakli-baskilayici-hucrelerin-rolu-dlbcl","12":"tag-tumor-mikrocevresinde-immunsupresif-hucre-artisi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Lenfomada-Myeloid-Baskilayici-Hucre-Dengesizligi-1745511284.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3790"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3790\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3791"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3790"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nPeriferik kanda bulunan miyeloid kaynakl\u0131 bask\u0131lay\u0131c\u0131 h\u00fccrelerin oranlar\u0131 ve fonksiyonlar\u0131ndaki anormalliklerin diffuse b\u00fcy\u00fck B h\u00fccreli lenfoma (DLBCL) hastalar\u0131ndaki de\u011ferlendirilmesi.<\/p>\n
\nAbnormal proportions and functions of myeloid-derived suppressor cells in peripheral blood of patients with diffuse large B-cell lymphoma<\/p>\n
\nhttps:\/\/doi.org\/10.1186\/s12885-025-14142-8<\/p>\n
\nScienmag.com<\/p>\n
\ndiffuse b\u00fcy\u00fck B h\u00fccreli lenfoma, DLBCL, miyeloid kaynakl\u0131 bask\u0131lay\u0131c\u0131 h\u00fccreler, MDSC, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi, imm\u00fcnosupresyon, hematolojik malignite, imm\u00fcnoterapi, ak\u0131\u015f sitometrisi, t\u00fcm\u00f6r mikro\u00e7evresi, T h\u00fccre fonksiyonlar\u0131, lenfoma tedavisi<\/p>\n","protected":false},"excerpt":{"rendered":"